Search Results

You are looking at 51 - 60 of 1,196 items for :

  • "characteristics" x
  • Refine by Access: All x
Clear All
Full access

Emily J. Martin, Andrew R. Bruggeman, Vinit V. Nalawade, Reith R. Sarkar, Edmund M. Qiao, Brent S. Rose, and James D. Murphy

(18.6%) underwent esophageal stent placement. Table 1 contains baseline patient characteristics stratified by intervention. The 2 groups differed in terms of race, tumor histology, tumor location in the esophagus, age, and Charlson comorbidity index

Full access

Kevin S. Scher, Juan-Sebastian Saldivar, Michael Fishbein, Alberto Marchevsky, and Karen L. Reckamp

scan after 8 weeks of erlotinib showed continued significant decrease in the right upper lobe mass and mediastinal lymphadenopathy. Table 1 Tissue Biopsy Characteristics In April 2010, the patient underwent right pneumonectomy with lymph

Full access

Saby George, Roberto Pili, Michael A. Carducci, and Jenny J. Kim

in search of biomarker of response to IL-2 that can be validated in subsequent studies. Table 1 Response by Baseline Characteristics The therapeutic armamentarium for metastatic RCC considerably expanded in the past several years with

Full access

Jia-Wei Lv, Yu-Pei Chen, Guan-Qun Zhou, Xu Liu, Ying Guo, Yan-Ping Mao, Jun Ma, and Ying Sun

subsequent publications, and to identify the trends of reporting quality and associated characteristics. Methods Data Source and Study Sample Data were obtained through the Aggregate Analysis of ClinicalTrials.gov (AACT) database, reflecting data

Full access

Ami M. Vyas, Hilary Aroke, and Stephen Kogut

explained portion of the gap is the sum of the differences between HR-positive and HR-negative women in terms of observed characteristics weighted by the pooled regression coefficients. It is calculated by multiplying the differences in the average

Full access

Rachel F. Dear, Kevin McGeechan, Megan B. Barnet, Alexandra L. Barratt, and Martin H.N. Tattersall

were extracted from ClinicalTrials.gov . Of these, 500 did not meet inclusion criteria, most because they did not use a drug intervention (80%; 400/500). Trials may have been excluded for more than one reason ( Figure 1 ). Characteristics of the 215

Full access

Christopher P. Chung, Carolyn Behrendt, Louise Wong, Sarah Flores, and Joanne E. Mortimer

classified according to the IIQ-7 score as major (33–99), moderate (5–29), or no impact (0). Statistical Analyses For this exploratory study, statistical significance ( P <.05) was unadjusted for multiple hypothesis testing. Demographic characteristics (age

Full access

Matthew P. Banegas, Donna R. Rivera, Maureen C. O’Keeffe-Rosetti, Nikki M. Carroll, Pamala A. Pawloski, David C. Tabano, Mara M. Epstein, Kai Yeung, Mark C. Hornbrook, Christine Lu, and Debra P. Ritzwoller

standards. 22 VTR data were obtained via chart review by trained abstractors and included data associated with health service use and clinical, treatment, and tumor characteristics. The VDW pharmacy files provided data on national drug code

Full access

Samuel Martel, Matteo Lambertini, Dominique Agbor-Tarh, Noam F. Ponde, Andrea Gombos, Vicki Paterson, Florentine Hilbers, Larissa Korde, Anna Manukyants, Amylou Dueck, Christian Maurer, Martine Piccart, Alvaro Moreno-Aspitia, Christine Desmedt, Serena Di Cosimo, and Evandro de Azambuja

original ALTTO trial. 10 Statistical Considerations Patient baseline characteristics were compared with respect to BMI category (underweight, normal weight, overweight, obese) using the chi-square test. Weight change was calculated as a percentage (by

Full access

Heidi Ko, Yaser Baghdadi, Charito Love, and Joseph A. Sparano

for categorical variables. Association Between Clinical Characteristics and Upstaging Frequencies Associations between clinical characteristics and upstaging frequencies were assessed using the Fisher exact test for categorical variables and the